BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21141731)

  • 21. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.
    Bernot KM; Siebenaler RF; Whitman SP; Zorko NA; Marcucci GG; Santhanam R; Ahmed EH; Ngangana M; McConnell KK; Nemer JS; Brook DL; Kulp SK; Chen CS; Frankhouser D; Yan P; Bundschuh R; Zhang X; Dorrance AM; Dickerson KE; Jarjoura D; Blum W; Marcucci G; Caligiuri MA
    Leukemia; 2013 Dec; 27(12):2379-82. PubMed ID: 23660685
    [No Abstract]   [Full Text] [Related]  

  • 23. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
    Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
    Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia.
    Weng H; Lal K; Yang FF; Chen J
    Cancer Genet; 2015 May; 208(5):225-9. PubMed ID: 25686674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association.
    Gebhard C; Glatz D; Schwarzfischer L; Wimmer J; Stasik S; Nuetzel M; Heudobler D; Andreesen R; Ehninger G; Thiede C; Rehli M
    Leukemia; 2019 Jan; 33(1):26-36. PubMed ID: 29925905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.
    Milan T; Celton M; Lagacé K; Roques É; Safa-Tahar-Henni S; Bresson E; Bergeron A; Hebert J; Meshinchi S; Cellot S; Barabé F; Wilhelm BT
    Haematologica; 2022 Jan; 107(1):86-99. PubMed ID: 33375773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures.
    Benedikt A; Baltruschat S; Scholz B; Bursen A; Arrey TN; Meyer B; Varagnolo L; Müller AM; Karas M; Dingermann T; Marschalek R
    Leukemia; 2011 Jan; 25(1):135-44. PubMed ID: 21030982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between epigenetic changes in Wnt antagonists and acute leukemia.
    Zhou HR; Fu HY; Wu DS; Zhang YY; Huang SH; Chen CJ; Yan JG; Huang JL; Shen JZ
    Oncol Rep; 2017 May; 37(5):2663-2671. PubMed ID: 28440495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
    Fiskus W; Mill CP; Birdwell C; Davis JA; Das K; Boettcher S; Kadia TM; DiNardo CD; Takahashi K; Loghavi S; Soth MJ; Heffernan T; McGeehan GM; Ruan X; Su X; Vakoc CR; Daver N; Bhalla KN
    Blood Cancer J; 2023 Apr; 13(1):53. PubMed ID: 37055414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.
    Yang XH; Wang B; Cunningham JM
    BMC Med Genomics; 2015; 8 Suppl 2(Suppl 2):S6. PubMed ID: 26043758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy.
    Deng R; Shen N; Yang Y; Yu H; Xu S; Yang YW; Liu S; Meguellati K; Yan F
    Biomaterials; 2018 Jun; 167():80-90. PubMed ID: 29554483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells.
    Aikawa Y; Yamagata K; Katsumoto T; Shima Y; Shino M; Stanley ER; Cleary ML; Akashi K; Tenen DG; Kitabayashi I
    Cancer Sci; 2015 Mar; 106(3):227-36. PubMed ID: 25529853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
    Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
    Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Key roles of histone methyltransferase and demethylase in leukemogenesis.
    Yoshimi A; Kurokawa M
    J Cell Biochem; 2011 Feb; 112(2):415-24. PubMed ID: 21268062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
    Marneth AE; Prange KHM; Al Hinai ASA; Bergevoet SM; Tesi N; Janssen-Megens EM; Kim B; Sharifi N; Yaspo ML; Kuster J; Sanders MA; Stoetman ECG; Knijnenburg J; Arentsen-Peters TCJM; Zwaan CM; Stunnenberg HG; van den Heuvel-Eibrink MM; Haferlach T; Fornerod M; Jansen JH; Valk PJM; van der Reijden BA; Martens JHA
    Leukemia; 2018 Mar; 32(3):828-836. PubMed ID: 28871137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromosomal translocations involving the MLL gene: molecular mechanisms.
    Aplan PD
    DNA Repair (Amst); 2006 Sep; 5(9-10):1265-72. PubMed ID: 16797254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In focus: MLL-rearranged leukemia.
    de Boer J; Walf-Vorderwülbecke V; Williams O
    Leukemia; 2013 Jun; 27(6):1224-8. PubMed ID: 23515098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.